Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 8 Nov 2026
Standard addition

First-line systemic treatment patterns and outcomes in lung cancer patients with malignant pleural effusion: a retrospective multicenter study.

Adding bevacizumab to chemotherapy improved survival in lung cancer patients with fluid around the lungs who lacked genetic driver mutations.

This PubMed-indexed study examined first-line systemic treatment patterns and outcomes in lung cancer patients with malignant pleural effusion: a retrospective multicenter study. First-line systemic therapy was associated with improved survival in lung cancer patients with MPE, though outcomes differed according to histologic and molecular subtypes The addition of bevacizumab to chemotherapy was independently associated with longer OS among patients with driver gene-negative NSCLC with MPE.

What the study was

Study design
Retrospective multicenter cohort study
Population
Human participants or human evidence described in the PubMed abstract
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
Journal of thoracic disease

Why it surfaced

Retrospective multicenter cohort study with PubMed abstract evidence; scored conservatively for genomics/precision medicine relevance and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.